PSA Specific Neutra™ Antibody Products

Are you grappling with prolonged drug development timelines or challenges in generating high-affinity antibodies against complex biomarkers? Creative Biolabs' PSA specific Neutra™ antibody products overcome these hurdles through advanced hybridoma screening and epitope-specific engineering, enabling rapid development of antibodies with exceptional specificity for PSA to enhance diagnostic accuracy and therapeutic efficacy.

Introduction to PSA

Prostate-specific antigen (PSA), a serine protease primarily secreted by prostate epithelial cells, is a well-established biomarker for prostate health. Its physiological role includes liquefying seminal fluid to promote sperm motility. However, dysregulated PSA expression is closely linked to pathological conditions, making it a critical target for research and clinical applications.

• Basic Information

PSA, encoded by the KLK3 gene, is a 33 kDa glycoprotein member of the kallikrein-related peptidase family. It is produced in both normal and malignant prostate tissues, with serum levels typically below 4 ng/mL in healthy individuals. Elevated PSA levels often correlate with prostate pathologies, though benign conditions like prostatitis can also cause transient increases.

• Structural Insights

PSA comprises a single polypeptide chain with 237 amino acids, including a catalytic triad (His57, Asp102, Ser195) essential for enzymatic activity. Its structure features three disulfide bonds stabilizing the core domain and a glycosylation site at Asn69, which modulates stability and interaction with substrates. Recent crystallographic studies reveal conformational flexibility in the antigen-binding regions, informing epitope-focused antibody design.

• Signaling Pathways and Functional Impact

PSA cleaves extracellular matrix proteins such as fibronectin and insulin-like growth factor-binding proteins (IGFBPs), releasing bioactive fragments that promote tumor angiogenesis and metastasis. It also activates protease-activated receptors (PARs) on cancer cells, driving proliferation and resistance to apoptosis. These pathways underscore PSA's dual role as a diagnostic marker and therapeutic target.

Fig.1 Mechanism of PSA release into the blood circulation.¹

• Disease Associations

PSA is most notably linked to prostate cancer, where its overexpression facilitates tumor progression and invasion. It is the gold-standard biomarker for screening and monitoring disease recurrence post-treatment. Additionally, chronic inflammation or hyperplasia of the prostate can elevate PSA levels, necessitating highly specific antibodies to distinguish malignant from benign conditions.

Applications of PSA-Specific Neutralizing Antibodies

• Precision Cancer Diagnostics

PSA-neutralizing antibodies enable ultrasensitive detection of serum PSA levels, crucial for early-stage prostate cancer diagnosis. By selectively capturing free PSA (fPSA) and complexed PSA (cPSA), these antibodies reduce false positives caused by benign conditions, improving diagnostic specificity.

• Therapeutic Response Monitoring

Quantifying PSA dynamics during androgen deprivation therapy or radiotherapy provides real-time insights into treatment efficacy. Neutralizing antibodies facilitate accurate tracking of PSA suppression, aiding in the timely adjustment of therapeutic regimens.

• Targeted Drug Conjugation

Antibody-drug conjugates (ADCs) leveraging PSA-specific antibodies deliver cytotoxic payloads directly to PSA-expressing cancer cells, minimizing off-target effects. This approach is being explored in metastatic castration-resistant prostate cancer (mCRPC) to enhance therapeutic precision.

• Prophylactic and Immunomodulatory Strategies

In high-risk populations, prophylactic administration of neutralizing antibodies may inhibit PSA-driven precancerous signaling. Preclinical models demonstrate reduced tumor incidence when PSA activity is blocked at early disease stages.

Our Anti-PSA Neutralizing Antibodies

Creative Biolabs' anti-PSA neutralizing antibodies are engineered to bind epitopes critical for PSA's proteolytic activity, effectively inhibiting its interaction with substrates. These antibodies exhibit cross-reactivity with free and complexed PSA forms while avoiding interference from homologous kallikreins like hK2. Validated in ELISA, immunohistochemistry (IHC), and chemiluminescent assays, they achieve picomolar sensitivity and >95% batch-to-batch consistency, ensuring reliability in both research and clinical settings.

Creative Biolabs' PSA Specific Neutra™ Antibody Products combine rigorous validation, unmatched specificity, and scalability to meet the demands of modern biomarker research and therapeutic development.

Contact our team today to explore custom solutions tailored to your project.

REFERENCE

REFERENCE

1. Zhang, Zhengchao, et al. "Application and optimization of prostate-specific antigen screening strategy in the diagnosis of prostate cancer: a systematic review." Frontiers in Oncology 13 (2024): 1320681. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fonc.2023.1320681